Menelas N. Pangalos
Menelas N. Pangalos's purchase track record
Menelas N. Pangalos has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/13/2026 | ABSI | $201K | +79.3% | pending | — |
| 2/27/2026 | ABSI | $206K | +146.3% | +218.3% | +12.1% |
| 9/22/2025 | ABSI | $255K | +36.4% | +8.9% | -1.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
ABSI to Report Q3 2026 Results on Nov 12, Shares Drop. Absci will announce its third‑quarter 2026 financials on Nov. 12. The company’s shares fell after a recent analyst note that the stock trades near the lower end of its 52‑week range and a new price target of $14.50. The drop follows a whale‑level buying alert and a broader market move higher for several large names. The upcoming earnings release may clarify the company’s outlook.
Transaction History
| BIIB | ▲ Buy | Option Exercise | 2,370 | $0 | 6/9/2026 | View on chart |
| BIIB | ▲ Buy | Grant | 1,505 | $0 | 6/9/2026 | View on chart |
| ABSI | ▲ Buy | Grant | 10,100 | $0 | 6/4/2026 | View on chart |
| ABSI | ▲ Buy | Open Market | 37,453 | $201K | 5/13/2026 | View on chart |
| ABSI | ▲ Buy | Grant | 5,800 | $0 | 3/2/2026 | View on chart |
| ABSI | ▲ Buy | Open Market | 75,095 | $206K | 2/27/2026 | View on chart |
| ABSI | ▲ Buy | Open Market | 95,785 | $255K | 9/22/2025 | View on chart |
| ABSI | ▲ Buy | Grant | 14,500 | $0 | 6/11/2025 | View on chart |
| ABSI | ▲ Buy | Grant | 3,675 | $0 | 6/12/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Biogen sees kidney therapy progress and rating upgrade
Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.
Biogen sees kidney therapy progress and rating upgrade. Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.